ReviewMethodist DeBakey cardiovascular journal2026
Cholesterol: Facts and Opinions by a Non-lipid Cardiologist.
Review in Methodist DeBakey cardiovascular journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma low-density lipoprotein cholesterol (LDL-C) is the main cause of coronary artery disease (CAD). All cells synthesize their own cholesterol when needed to form membranes for the cell wall and other cellular structures, including the synthesis of vitamin D. Cholesterol in excess of the cell's needs is dumped into the bloodstream to be metabolized by the liver and secreted into the intestine. Of the circulating cholesterol, 80% is derived from this excessive endogenous cholesterol, with only a small proportion from diet. Thus, it is not surprising that lowering plasma LDL-C to levels as low as 5 to 10 mg/dL is associated with further reduction in cardiac events and no apparent increase in adverse events. Individuals at increased risk for CAD should embrace a more favorable lifestyle and simultaneously be started on a lipid-lowering agent, which initially should be a statin. Taken by hundreds of millions of patients for over three decades, statins are highly efficacious and safe and are said to be safer than aspirin. Although the plasma LDL-C level for optimal efficacy and safety has yet to be determined, the future goal is likely to be around 40 mg/dL, a level observed in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.